Biotech News Brief

Biotech news for Saturday, August 22, 2026, ranked by our 5-dimension investment framework — regulatory, technology, commercial, manufacturing, and narrative.

Strong Buy · 90/100Aug 20, 4:17 AM EDT

Moderna Stock Soars 177% on Cancer Vaccine Data, Yet Analyst Warns of Turbulence Ahead

MRNAMUMRK

Moderna (MRNA) shares skyrocketed 176.97% to $174.38 on Wednesday, the biggest single-day jump for an S&P 500 stock this century, after positive late-stage trial results for its personalized mRNA cancer vaccine developed with Merck (MRK). While the news is a m…

▹Positive Phase 3 results for personalized mRNA cancer vaccine with Merck, a major catalyst.
▹Platform technology with multiple assets and big pharma partnership, strong manufacturing and regulatory support.

Strong Buy · 80/100Aug 20, 4:50 AM EDT

Trump Boosts Moderna Stake with Two New Purchases

MRNA

President Trump's recent stock filing reveals two purchases of Moderna (MRNA) shares, totaling between $16,002 and $65,000, with trade dates in March. This insider buying could signal confidence in the company's prospects, potentially boosting investor sentime…

▹Trump's stock purchases signal confidence, potentially boosting investor sentiment.
▹Moderna's mRNA platform is a strong technology moat with multiple products in pipeline.

← Back to the latest News Brief